to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Numerous factors affect how angels value a company. Primary are the strength of the management team and the size of the opportunity, or a company's potential to scale. Accompanying this article is a valuation worksheet that entrepreneurs can use to better understand what investors look for and to identify factors that can justify higher pre-money valuations. Investors will find it useful to compare companies and determine whether valuation should be higher or lower.
A highly successful angel investor and entrepreneur identifies and puts to the test a valuation calculator tool. He finds that it works very well, thank you. By answering twenty-five questions, entrepreneurs and investors arrive at valuations that can reasonably be used as a practical guide to investing.
This informative piece explains a well-known method that venture capitalists use to determine "post-money valuation," which is a company's valuation at the time of investment. Perhaps more important, it provides valuable insights into why the returns expected by investors are often perceived as "too high" by entrepreneurs.
What's the best strategy for developing and launching a new medical device? The uncertainty of the regulatory and reimbursement environment in the United States has made venture capitalists wary of investing in new medical device companies, but that doesn't mean all is lost.
A healthcare VC predicts that more DNA sequencing and the shift from patients to healthcare consumers, among other things, will rule the future of healthcare innovation.
London's Alternative Investment Market (AIM) is a credible alternative for U.S. companies looking for a market listing. As with any approach to IPO, U.S. companies should research AIM's advantages and disadvantages for listing compared with U.S. stock markets.
One of George Bush's most memorable lines was his complaint that the French had no word for "entrepreneur". Well, if Senator Dodd's new financial reform bill becomes law, we may well have the word, but no longer any need for it.
We're looking for a champion. A courageous entrepreneur with shoulders broad enough to bear the hopes and dreams of the entire country across the Atlantic to represent America at a global contest of pitching pugilism.
Innovation Fund America (IFA), our program delivering high-impact education, coaching and pre-seed funding to scalable, technology-based startups via community colleges around the country, has quietly been having a big couple of months. It's a complicated and demanding program to launch and it's taken nearly a year and a half to get to this point, but we're excited that IFA is now open for business in two communities--and we're really just getting started.
Bradmer Pharmaceuticals, an American biotech company, chose to use the Toronto Venture Exchange's Capital Pool Company Program to raise cash in the public markets. The author shares his experience making the decision to list in the CPC program and his lessons learned.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.